Trial Site Detail
Drug: |
Selumetinib |
|||
|---|---|---|---|---|
Trial: |
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) |
|||
| Conditions: | NF1 GIST | |||
Trial Status: |
Withdrawn |
|||
National Cancer InstituteBuilding 10, Room 4-3760 10 Center Drive |
Principal Investigator: |
Brigitte C. Widemann, MD |
|---|---|
Contact: |
Claudia P Derse-Anthony 240-760-6102 claudia_derse-anthony@nih.gov |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
National Cancer Institute Website: |
http://www.cc.nih.gov/index.html |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.